NVAX Q3 2022 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$735M+310.7% YoY

Gross Profit

$300M40.8% margin

Operating Income

-$127M-17.3% margin

Net Income

-$169M-23.0% margin

EPS (Diluted)

$-2.15

QoQ Revenue Growth

+295.1%

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$68M

Stock-Based Comp.

$32M

Balance Sheet

Total Assets

$2.3B

Total Liabilities

$2.8B

Stockholders' Equity

-$566M

Cash & Equivalents

$1.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$735M	$179M	+310.7%
Gross Profit	$300M	$179M	+67.7%
Operating Income	-$127M	-$307M	+58.6%
Net Income	-$169M	-$322M	+47.7%

Revenue Segments

Product

$626M85%

Grant

$106M14%

Royalties and Other

$2M0%